SAMSUNG BIOLOGICS Co., Ltd. 207940

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the tender offer prospectus ("Offer Prospectus") for all publicly held registered shares of PolyPeptide Group AG ("PolyPeptide").

Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion.

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the second quarter of fiscal year 2026.

Executive vice-president James Choi discusses the CDMO’s growth strategy and acquiring its first US manufacturing site from GSK.

Completion of the deal is anticipated towards the end of 2026.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG ("PolyPeptide") (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).

South Korea's centrifugation market is poised for significant expansion, with projections hitting $92.7 million by 2035. This growth is fueled by the country's robust biopharmaceutical sector, advanced clinical research infrastructure, and strong government investments in life sciences. Centrifugation, vital for applications like protein purification and vaccine production, has evolved into sophisticated GMP-compliant systems integral to large-scale manufacturing. Companies such as Samsung Biolo

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental, social, and governance (ESG) report, highlighting continued progress in sustainable operations, responsible business practices, and governance.

A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has been included in the Dow Jones Best-in-Class World Index (formerly the Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the company's continued commitment to sustainable growth and responsible business practices.

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.

The US facility boosts local biomanufacturing, preserves jobs, and signals further growth in Maryland’s life sciences sector.

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.